AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05097521 — intervention group
Intervention type: OTHER
Intervention: Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings
Description: Self-care CIH therapies (yoga, Tai Chi/Qigong , meditation) as received in VHA and community practice settings
Study NCT05097521 — intervention group
Intervention type: OTHER
Intervention: Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings
Description: Combination of practitioner-delivered and self-care CIH therapies (described above) as received in VHA and community practice settings
Study NCT05281133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The group using virtual reality glasses
Description: The video chosen by the children in the experimental group was started 1-2 minutes before the splint with virtual reality glasses and watched for an average of 7 minutes.
Study NCT05753267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalamine
Description: Mesalamine (also known as mesalamine or 5- amino salicylic acid, 5-ASA) has a well-established role in UC management. It is the first line therapy for mild to moderate UC and it is considered the cornerstone in the management of UC
Study NCT05753267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate 160mg
Description: Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia.
Study NCT06303284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: subcutaneous Teriparatide injection
Description: 20 µg subcutaneous (SC) Teriparatide injection
Study NCT06303284 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: placebo 20 µg subcutaneous saline placebo injection once daily for 3 months in the post-operative ankle fracture population.
Study NCT05501938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Exam Indicated Cerclage
Description: Transvaginal cervical cerclage
Study NCT04472520 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AliveCor Heart Monitor
Description: Records single-channel ECG rhythms
Study NCT05284279 — intervention group
Intervention type: OTHER
Intervention: Exploring health professionals' perceptions of patients with ECC using semi-structured interviews
Description: Following a literature review on the topic of children with ECC and their family, a guidebook will be built by main investigators. Several test interviews will be conduct to ensure that guidebook is adapted, and that the interviewer is enough trained.~Interview will be conducted by one or two of the main investigators. As much as possible, they will be performed face to face or using videoconference due to COVID19 pandemic context. All the interviews will be audio recorded. The interviewer will take notes including non-verbal communication; and will adopt an active listening position.~After collecting respondents' characteristics (age, gender, profession, exercise duration, type of practice), the subsequent themes will be explored: disease perception, educational context's responsibility, barriers and facilitators to family behaviour changes, health professional's emotional consequences.
Study NCT03988231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Receipt of enoxaparin
Description: Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
Study NCT03988231 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be randomized to enoxaparin 40mg once daily versus saline placebo at 8 hours after surgery and continued for the duration of inpatient stay.
Study NCT04646785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy + TAU
Description: The proposed intervention is mindfulness-based cognitive therapy (MBCT), based on the protocol published by Segal, Williams and Teasdale. MBCT consists of eight weekly 2.5h group sessions, a six-hour silent day and daily home practice assignments guided by audio files. The program includes both formal and informal meditation exercises. Cognitive techniques include monitoring and scheduling of activities, identification of negative automatic thoughts and devising a relapse prevention plan. Psycho-education and interactive dialogue typically focus on stress management, balancing activities, and (lifestyle) strategies to stay well in the future (relapse prevention).
Study NCT04646785 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Treatment as usual (TAU) according Dutch and European IBD treatment guidelines. TAU focuses on pharmacological and surgical disease control, and prevention of complications.
Study NCT04533490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: After the subjects were enrolled in the study, the patients were treated with SHR-1210 200mg igvtt q3w from 1 to 2 months after operation until disease progression or intolerable toxicity, and the longest medication period was no more than 12 months
Study NCT05973552 — intervention group
Intervention type: OTHER
Intervention: CO-rebreathing
Description: In the CO-rebreathing method, a dedicated apparatus is used for inhaling and rebreathing a very small bolus of CO through a spirometer for \~2 min, which is absorbed through the lungs and binds to Hb, and then the increase of HbCO content of blood is measured 8 min after the CO inhalation. The increase of COHb in blood samples can then be used to precisely calculate Hb mass and blood volume
Study NCT05973552 — intervention group
Intervention type: OTHER
Intervention: Oral iron isotope administration (54Fe)
Description: Participants randomly assigned to the sub-group, will receive 54Fe with a test meal in the second and third trimester for assessment of dietary iron absorption
Study NCT05973552 — intervention group
Intervention type: OTHER
Intervention: Intravenous iron isotope administration (58Fe)
Description: Participants randomly assigned to the sub-group, will receive intravenous 58Fe in the second and third trimester for assessment of erythrocyte iron incorporation
Study NCT05304650 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: iTEAR100
Description: Controlled Stimulation External Nasal Nerve to stimulate tear production
Study NCT06071767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1.tHIVconsv1
Description: Administered as 0.4 mL intramuscularly (IM) at Week 0
Study NCT06071767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1.HIVconsv62
Description: Administered as 0.3 mL IM at Week 0
Study NCT06071767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.tHIVconsv3
Description: Administered as 0.3 mL IM at Week 4
Study NCT06071767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.tHIVconsv4
Description: Administered as 0.5 mL IM at week 4
Study NCT06071767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vesatolimod (VES)
Description: VES 6 mg administered orally once every 2 weeks for two doses, then VES 8 mg once every 2 weeks for 8 doses. Dose escalation may be held or the 8 mg dose may be reduced for intolerability for weeks 6 through 24.
Study NCT06071767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5423
Description: Administered via intravenous (IV) infusion at week 7
Study NCT06071767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-2872
Description: Administered via IV infusion at week 7
Study NCT06071767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.tHIVconsv4
Description: Administered 0.5 mL IM at week 60
Study NCT06071767 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebos for vaccines, VES, and bnAbs
Study NCT05301920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elexir (trigeminal nerve electrical stimulator)
Description: Elexir performs a personal electrical stimulation around the trigeminal nerves for 4weeks (6 times/week), 20 minutes each time.
Study NCT05060705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efesovir
Description: Antiviral therapy of COVID19 with Efesovir oral solution in dose 0.125 ml / kg two times per day. Duration of treatment is 5 - 10 days, depending on the severity of the disease.
Study NCT05060705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efesovir
Description: Antiviral therapy of COVID19 with Efesovir oral solution in dose 0.125 ml / kg two times per day. Duration of treatment is 5 - 10 days, depending on the severity of the disease.
Study NCT05742997 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PartoSure
Description: Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1
Study NCT05742997 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fetal Fibronectine
Description: Diagnostic Kit for the Detection of Fetal Fibronectine
Study NCT04577729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogenic Fecal Microbiota Transplantation
Description: Patients receiving stool from prior malignant melanoma (MM) patients in remission for at least 1 year after Checkpoint Inhibitor Treatment.
Study NCT04577729 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Autologous Fecal Microbiota Transplantation
Description: Patients receiving their own stool in terms of sham FMT.
Study NCT06395233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BetterPoints App
Description: The BetterPoints app is a smartphone application that uses incentives and gamification to motivate physical activity.
Study NCT04662944 — intervention group
Intervention type: DRUG
Intervention: brolucizumab
Description: There was no treatment allocation. Patients administered Brolucizumab by prescription that started before inclusion of the patient into the study were enrolled.
Study NCT04662944 — intervention group
Intervention type: DRUG
Intervention: ranibizumab
Description: There was no treatment allocation. Patients administered Ranibizumab by prescription that started before inclusion of the patient into the study were enrolled.
Study NCT04662944 — intervention group
Intervention type: DRUG
Intervention: aflibercept
Description: There was no treatment allocation. Patients administered Aflibercept by prescription that started before inclusion of the patient into the study were enrolled.
Study NCT06490276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait training with biofeedback
Description: Gait training include treadmill and overground walking. The biofeedback device system will provide real-time feedback on hip extension angles.
Study NCT06490276 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gait training without biofeedback
Description: Gait training include treadmill and overground walking.
Study NCT05239611 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The intervention for all participants will be delivered by two pulmonary rehabilitation coaches (PR-coach) including a registered respiratory therapist and clinical registered dietitian who've been trained in exercise training as recommended by the AACVPR and American College of Sports Medicine (ACSM). Each TR participant will be assigned a PR-coach, and receive one weekly exercise consulting session during the 12-week intervention.
Study NCT05054647 — intervention group
Intervention type: OTHER
Intervention: psychometric questionnaires
Description: Perceived Stress Scale (PSS-10); Trier-Inventory on Chronic Stress; State/Trait Anxiety Inventory (STAI); AVEM-Work-related behaviour and experience pattern; Maslach Burn-out Inventory - Human Services Survey (MBI - HSS) health-related anxiety: Whiteley Index (WI)
Study NCT06428084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 4 mg of ondansetron intravenously
Study NCT06428084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: 1 mg of Haloperidol intravenously
Study NCT05311670 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient-reported outcomes monitoring
Description: o Patient-reported outcomes will be collected from patients through web or telephone and alerts sent to providers.
Study NCT05511974 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: BASET score
Description: The patients were divided into two groups. Group I (study group): consist of sixty-three patients having OSA. Group II (control group): consist of eighty-one non-OSA patients
Study NCT04137120 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (BAY86-5321, Eylea)
Description: Intravitreal injection of aflibercept as scheduled by treating physician
Study NCT06508918 — intervention group
Intervention type: DRUG
Intervention: Betametasona
Description: pressure pain threshold values of the most painful area will be recorded with a manual algometer
Study NCT06448702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wet wrap therapy
Description: Steps for wet wrap therapy After bath/shower with emollients, pat to remove excess water on body and apply the emollient and/ or steroid cream liberally on the affected area to enhance water absorption and seal in moisture Put wet wrap garment in lukewarm water, squeeze water out of the wet wrap garment, take them out without dribbling of water and then apply on the affected area Put on another layer of dry garments/ warm clothing to cover the wet wrap garments and wear usual clothing as needed Check regularly and keep the wet wrap garments underneath damp with water sprayer or wet towel if necessary Patient is suggested to apply emollients frequently throughout the day to maintain the effect
Study NCT06448702 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External compression counter-pulsation (EECP)
Description: External compression counter-pulsation (EECP) is a compression/decompression non-invasive device (Stendo Pulsewave ® V3 CE certificate class IIa) used for lower part of the body (legs, thighs and buttock/hips) to reproduce and stimulate the natural physiological pulsations and the physical shear stress force.
Study NCT05296642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Cycling
Description: Using the recumbent bicycle (95Ri, Life Fitness, Illinois) participants will be asked to sustain a moderate pace of 13 - 16 for 20 minutes of perceived exertion range using the Borg rate of perceived exertion scale (RPE).
Study NCT05296642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Tourniquet System
Description: An automated personalize tourniquet system (Delfi Medical, Inc., Vancouver, BC, Canada) will be used to perform blood flow restriction during BFR+AE. This system has a dual-purpose tourniquet cuff (11.5 x 86 cm) connected by airtight hose tubing to a personalized tourniquet device. The device automatically measures LOP and regulated pressure during exercise within clinically acceptable limits. Participants will be asked to lie in supine and a non-shedding stockinette protection sleeve will be placed at bilateral proximal thighs. Following, a tourniquet cuff will be placed bilaterally around the protection material and connected to the airtight hose tube.
Study NCT05150600 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inverse Ratio Ventilation
Description: The inspiratory to expiratory (I:E) ratio will be reversed to be 2:1 during mechanical ventilation
Study NCT06044207 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pittsburgh sleep quality index
Description: The scale is suitable for evaluating sleep quality in patients with sleep disorders and psychiatric disorders, as well as for assessing sleep quality in the general population.
Study NCT06044207 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Self-rating depression scale
Description: The scale is easy to use, can fairly intuitively reflect whether the patient has depression and the degree of depression, has been widely used in outpatient gross screening, mood state assessment.
Study NCT06044207 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Montreal Cognitive Assessment
Description: The scale is a tool used for rapid screening of mild cognitive dysfunction to identify patients with preoperative cognitive dysfunction
Study NCT05505136 — intervention group
Intervention type: DEVICE
Intervention: Arrhythmia Management System (AMS)
Description: Retrospective collection of data related to subjects who participated in the MAPS 90D0234 study and had a medication change reported will wearing the AMS device.
Study NCT05421312 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sampling blood
Description: During the reimplantation, 3 serum samples will be taken at different timepoint during the procedure.
Study NCT05421312 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sampling synovial fluid
Description: During the reimplantation 1 synovial fluid sample will be taken prior to incision.
Study NCT05048992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ELDOA method
Description: group A will receive
Study NCT05048992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-facilitation stretching
Description: Group B will receive
Study NCT05718609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: proton-pump inhibitor (PPI)
Study NCT05718609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: proton-pump inhibitor (PPI)
Study NCT05718609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colloidal Bismuth Pectin Granules
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT05718609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Bismuth Pectin Granules
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study NCT05718609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT05718609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT05718609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone
Description: Antibiotic for H. pylori eradication
Study NCT05718609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Antibiotic for H. pylori eradication
Study NCT05718609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Antibiotic for H. pylori eradication
Study NCT06304389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroencephalography, electrocardiogram, pupillometry, evoked potentials, light administration
Description: Recording of the electrical activity of the brain, of the heart. Pupil size will be analyzed. The effect of blue light administration will be assessed on those parameters.
Study NCT06304389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation, electroencephalography, pupillometry, electrocardiogram, light administration
Description: Transcutaneous vagus nerve stimulation will be performed in helathy subjects, as well as the recording of the electrical activity of the brain, and of the heart. Pupil size will be analyzed. The effect of blue light administration will be assessed on those parameters.
Study NCT06261970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect
Description: Community level enhancements
Study NCT04897802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: GLP1-RA (exenatide) administration
Description: a single dose of 10 mcg of GLP-RA (exenatide) will be administered subcutaneously and samples to assess OT secretory patterns will be collected over 2 hours
Study NCT04897802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control: Placebo administration
Description: Sodium Chloride 0.9% will be administered subcutaneously at equivalent volume than 10 mcg of exenatide
Study NCT05421312 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sampling bone tissue
Description: During the reimplantation 2 cortical bone samples will be taken at different timepoints during the procedure.
Study NCT04897477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine, Bendamustine and Piamprizumab
Description: Azacytidine by means of subcutaneous injection, Bendamustine and Piamprizumab intravenous infusion
Study NCT06001112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cheek acupuncture
Description: Based on the theory of holography and the theory of the Great Sanjiao, the acupoints were chosen under the guidance of the foundation of cheek acupuncture, selecting bilateral Sanjiao acupoints, bilateral head acupoints, foot and ankle acupoints on the affected side, and matching acupuncture points for local strengthening of the foot and ankle acupuncture points, using the triangular needle strengthening method. The treatment was performed with the patient lying on his back in a comfortable position, with routine local disinfection, rapid transdermal needle entry to the acupuncture points, and needle discharge after 30 minutes of needle retention, after which the needle hole was compressed with a cotton ball for a few moments.
Study NCT06001112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: etoricoxib 120mg
Study NCT04570501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin-(1-7)
Description: Ang (1-7) administered by continuous intravenous (IV) infusion
Study NCT04570501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (normal saline) administered by continuous intravenous (IV) infusion
Study NCT06090851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: herbal nitrate Pralines with nitrate
Description: consumption of herbal pralines with nitrate